The Oncologist 2017;22:375–376; first published on March 8, 2017; http://dx.doi.org/10.1634/theoncologist.2016-0133
In the Clinical Trial Results “Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer”, published in the April 2017 issue of The Oncologist, the affiliation for Dr. Jacek Jassem was incorrect. The correct affiliation is Medical University of Gdansk, Gdansk, Poland. This error has been corrected in the online version of the article.